As a young start-up, Invitrometrix is grateful of the support provided by many individuals with extensive knowledge in their fields of expertise.
Dr. Mike MorinPresident & CSO at Immunome
Dr. Morin is President and Chief Executive Officer of Immunome. He has had a productive career in cancer research, with a long-standing commitment to improving patient care. As Vice President of Pfizer Global R&D, overseeing Antibacterial, Immunology and Cancer drug discovery in Groton, CT.
During his 17-year Pfizer career, Dr. Morin led in the discovery of approximately 40 clinical candidates, many of which remain in active development. Most notable among these therapeutics was Dr. Morin’s direct leadership in the discovery through Phase 2 proof-of-concept for erlotinib (Tarceva™), a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase (a blockbuster drug marketed now by Roche and Astellas). Dr. Morin also led the group responsible for the discovery and development of tofacitinib (Xeljanz™), a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis that received marketing approval in 2012.
Since 2008, Mike has been working as an advisor and as C-level interim leader of different venture-backed biotechnology and publicly held pharmaceutical companies. Included among these were positions at Supportive Therapeutics (CEO) and Onkaido (CSO). Dr. Morin is a member of the Invitrometrix Scientific Advisory Board.
Dr. Adam HillCTO at Triple Sharp Venture Engineering
Dr. Adam Hill has had 20 years in Pharmaceutical companies mainly in early drug discovery. He is the CTO for an early stage Venture Company, Triple Sharp Venture Engineering. Dr Hill is focused on impacting patients lives - bringing efficiency and effectiveness to discovering new medicines. He is a pioneer of the implementation of new technologies in life sciences.
Previously, Dr. Hill was a founder and CEO of Prospective Research, Inc., a startup company focused on antibiotic discovery; in particular, novel compounds effective against gram negative bacteria with a new mechanism of action.
Dr. Hill was a director at Novartis, managing a group of 65 in Screening for CPC Cambridge engaged in early drug discovery - including sample management, cell engineering, assay development, high throughput screening using biochemical, cell and phenotypic readouts, and follow up. He has experience in safety pharmacology, in silico approaches and biophysics. Dr. Hill is a member of the Invitrometrix Scientific Advisory Board.
Steve ChomiczFounder of Seahorse Bioscience
Global Vice President of Sales and Marketing for Seahorse Bioscience (acquired by Agilent Technologies)
Steve Chomicz was one of the key players and founders in creating the flow cytometry & monoclonal antibody market from 1979 – 1998. In 2001 he was a founder of Seahorse bioscience and was a key player in developing the cellular metabolic analyzer market. It's rare to be involved in one major market creation and having a chance to develop a second new market was a dream come true.
The Seahorse instruments measure how cells breath in response to drugs and disease. Like the cardiac stress test detects cardiac problems we have a cell stress test which detects problems in cell metabolism. We have over 10,000 customers, 2,500 publications including many in Nature and Cell. And in 2015 we introduced a low cost metabolic analyzer which should be purchased by every lab working with cells.
Seahorse was sold to Agilent Technologies for $242 million, and has subsequently been working by providing his experience in guiding a new company to a successful outcome.
George GoodliffeDirector at 908 Devices
Former Director of North American sales with Seahorse Bioscience (acquired by Agilent Technologies)
Brian DrankaLife Science Leader
Head of Biology and Application Development formerly with Seahorse Bioscience (acquired by Agilent Technologies)
Brian Dranka is a scientist with 10 years of experience leading teams to build market-defining research products. Most recently, he was the product roadmap architect for a high-growth line of business at Agilent Technologies. He worked with customers from pharma and academic research labs to measure cell function in novel ways. Now he is looking to lead companies through their shift from technology push to market pull by identifying, developing, and delivering high-value, evidence-based, customer-centric solutions.
Henry KayAngel Investor
Henry Kay is currently serving on the boards of directors of several Life science companies in the US and Canada. He is an active Angel Investor and member of Boston harbor Angels and sky Venture Group. Angel Investor and member of Boston harbor Angels and sky Venture Group.
Mike RivardTriunity Law LLC
TriUnity Law Group seamlessly integrates law, business and technology to provide insight, solve problems, and deliver exceptional value for life sciences companies. Mike Rivard is a managing member at TriUnity Law Group LLC. He is an accomplished legal and business executive with over 20 years of experience, including over 15 years at the vice president level in public and private biotechnology companies.Closed more than 50 deals including collaborations, mergers & acquisitions, licenses, university-industry technology transfer, and public and private financings. Developed and implemented intellectual property strategy for four biotechnology companies in diverse technology fields.
David NeafusTriton Resources Inc
Triton is a boutique CFO consulting firm providing hands-on financial, HR, and administrative services to a wide variety of companies/industries. David Neafus is the founder and CEO of Triton Resources. Seasoned financial and operating executive specializing in startups, turnarounds, IPO's, M&A, debt financing, & equity financing. Substantial experience working with boards of directors. Significant experience in BioTech, HighTech, CleanTech, Manufacturing, distribution and others. CFO of more than 75 companies over the past several years. Triton Resouces has a staff of finance and HR professionals that assist in the total outsourcing of the finance and HR functions.